Is cancer gene therapy an empty suit?

Malcolm Brenner; Stephen Gottschalk; Ann M. Leen; Juan F. Vera

doi:10.1016/S1470-2045(13)70173-6

Is cancer gene therapy an empty suit?

Malcolm Brenner, Stephen Gottschalk, Ann M. Leen, Juan F. Vera

Research output: Contribution to journal › Review article › peer-review

49 Scopus citations

Abstract

Gene therapy as a treatment for cancer is regarded as high in promise, but low in delivery, a deficiency that has become more obvious with ever-increasing reports of the successful correction of monogenic disorders by this approach. We review the commercial and scientific obstacles that have led to these delays and describe how they are progressively being overcome. Recent and striking successes and correspondingly increased commercial involvement suggest that gene transfer could finally become a powerful method for development of safe and effective cancer therapeutic drugs.

Original language	English (US)
Pages (from-to)	e447-456
Journal	The Lancet Oncology
Volume	14
Issue number	11
DOIs	https://doi.org/10.1016/S1470-2045(13)70173-6
State	Published - Oct 2013

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(13)70173-6

Cite this

@article{c6cd0ef15e8b4a3d9cae0b78992af2ac,

title = "Is cancer gene therapy an empty suit?",

abstract = "Gene therapy as a treatment for cancer is regarded as high in promise, but low in delivery, a deficiency that has become more obvious with ever-increasing reports of the successful correction of monogenic disorders by this approach. We review the commercial and scientific obstacles that have led to these delays and describe how they are progressively being overcome. Recent and striking successes and correspondingly increased commercial involvement suggest that gene transfer could finally become a powerful method for development of safe and effective cancer therapeutic drugs.",

author = "Malcolm Brenner and Stephen Gottschalk and Leen, {Ann M.} and Vera, {Juan F.}",

note = "Funding Information: We are grateful for long-term support from the US National Institutes of Health (National Cancer Institute and National Institute of Health Heart, Lung and Blood Institute), the Department of Defense, and the Leukemia and Lymphoma Research Fund. We are also grateful to the foundations who have supported the centres investigators, including Alex's Lemonade Stand, Clayton Foundation for Research, V Foundation, Dana Foundation, James S McDonnell Foundation, Adrienne Helis Medical Research Foundation, and Bear Necessities Pediatric Cancer Foundation. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.",

year = "2013",

month = oct,

doi = "10.1016/S1470-2045(13)70173-6",

language = "English (US)",

volume = "14",

pages = "e447--456",

journal = "The Lancet Oncology",

issn = "1470-2045",